Shots: Halozyme to receive $25M upfront plus $160 to $165M/target milestones payments based on development, regulatory & sales in addition to royalties. Roche to get rights for ENHANZE Technology for exclusive development of clinical stage candidates for therapy areas Roche also has an option to add two additional targets within a span of four years, […]Read More
Tags : Rituxan Hycela & Herceptin
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US